Omeros Corporation

356 articles with Omeros Corporation

• Omeros' Extended Improvement in OMS721-Treated Patients With IgA Nephropathy Presented at American Society of Nephrology Annual Meeting

  11/6/2017

  During the Phase 2 clinical trial, which consisted of 12 weeks of treatment and 6 weeks of follow-up, all patients with IgA nephropathy demonstrated clinically meaningful improvement in proteinuria.

• Omeros to Announce Third Quarter 2017 Financial Results on November 9, 2017

  11/6/2017

  Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.

• Omeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual Meeting

  11/1/2017

  The presentation will be made at the American Society of Nephrology Meeting, which is being held October 31 through November 5 in New Orleans.

• Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

  10/26/2017

  Omeros today announced further positive data from the company's ongoing Phase II study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

• Omeros Reports Successful OMS721 Treatment of Patient With Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-Versus-Host Disease

  10/20/2017

  The results may expand target for Omeros' planned phase 3 program in HCT-TMA.

• Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation

  10/16/2017

  Omeros today announced that data will be presented from the company’s Phase II clinical trial of OMS721,

• Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Par

  10/6/2017

• Seattle's Omeros Fires Back But Still Won't Answer Basic Questions About Key Drug

  8/24/2017

• Omeros Closes $68.3 Million Public Offering Of Common Stock

  8/22/2017

• Omeros Data Show Continued Improvement In Patients With IgA Nephropathy Treated With OMS721

  8/15/2017

• Omeros Announces Public Offering Of Common Stock

  8/15/2017

• Omeros Announces Pricing Of Public Offering Of Common Stock

  8/15/2017

• Omeros To Present At The 2017 Wedbush Pacgrow Healthcare Conference

  8/10/2017

• Omeros Reports Second Quarter 2017 Financial Results

  8/9/2017

• FDA Grants Orphan Drug Designation To Omeros’ OMS721 For Treatment Of IgA Nephropathy

  8/4/2017

• Omeros To Announce Second Quarter 2017 Financial Results On August 8, 2017

  8/2/2017

• Omeros: Next Big Thing In Biotech

  7/5/2017

• Omeros Pursuing Legal Action Against Short Seller for Report That Caused Stock to Tank This Week

  6/30/2017

• Omeros Releases Statement In Response To Recent False Report

  6/29/2017

• FDA Calls Omeros' Kidney Disorder Drug a Breakthrough

  6/13/2017